Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007269
Filing Date
2025-05-12
Accepted
2025-05-12 09:00:36
Documents
87
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20250331x10q.htm   iXBRL 10-Q 2506814
2 EX-31.1 btai-20250331xex31d1.htm EX-31.1 17274
3 EX-31.2 btai-20250331xex31d2.htm EX-31.2 17081
4 EX-32.1 btai-20250331xex32d1.htm EX-32.1 10254
5 EX-32.2 btai-20250331xex32d2.htm EX-32.2 8687
6 GRAPHIC btai-20250331x10q006.jpg GRAPHIC 88924
7 GRAPHIC btai-20250331x10q007.jpg GRAPHIC 81075
  Complete submission text file 0001558370-25-007269.txt   10315954

Data Files

Seq Description Document Type Size
8 EX-101.SCH btai-20250331.xsd EX-101.SCH 62958
9 EX-101.CAL btai-20250331_cal.xml EX-101.CAL 42809
10 EX-101.DEF btai-20250331_def.xml EX-101.DEF 286283
11 EX-101.LAB btai-20250331_lab.xml EX-101.LAB 545941
12 EX-101.PRE btai-20250331_pre.xml EX-101.PRE 431122
90 EXTRACTED XBRL INSTANCE DOCUMENT btai-20250331x10q_htm.xml XML 1675478
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 25932837
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)